Abnormal mitochondrial function and morphology in heart transplanted patients with cardiac allograft vasculopathy

Emil Dariush Lichscheidt1, Nichlas Riise Jespersen2, Bent Roni Ranghøj Nielsen2

  • 1Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Insights

Cardiac allograft vasculopathy (CAV) impairs heart transplant survival. This study found reduced mitochondrial respiration and abnormal mitochondrial structure in CAV patients, linked to decreased heart function. Mitochondrial treatments may benefit these patients.

Area of Science:

  • Cardiology
  • Mitochondrial Medicine
  • Transplantation Science

Background:

  • Cardiac allograft vasculopathy (CAV) significantly impacts long-term survival in heart transplant (HTx) patients.
  • Mitochondrial dysfunction is implicated in cardiovascular diseases, but its role in HTx patients with CAV is unexplored.

Purpose of the Study:

  • To investigate myocardial mitochondrial function in heart transplant recipients with and without CAV.
  • To correlate mitochondrial function with cardiac performance and biomarkers in CAV patients.

Main Methods:

  • Analysis of endomyocardial biopsies from 43 HTx patients (21 with CAV, 22 without CAV) using high-resolution respirometry.
  • Assessment of mitochondrial morphology via transmission electron microscopy.
  • Correlation of mitochondrial function with global longitudinal strain (GLS) and cardiac biomarkers (Troponin T, NT-proBNP).

Main Results:

  • Patients with CAV exhibited reduced Complex I+II-linked mitochondrial respiration compared to those without CAV.
  • Impaired mitochondrial respiratory function correlated with reduced left ventricular GLS and elevated cardiac biomarkers.
  • CAV patients showed a higher proportion of mitochondria with abnormal cristae morphology, despite no differences in mitochondrial number or area.

Conclusions:

  • Myocardial mitochondrial respiration is impaired in heart transplant recipients with CAV.
  • This impairment is linked to abnormal mitochondrial structure and reduced cardiac contractile function.
  • Mitochondrial-targeted therapies warrant investigation for patients with CAV.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
55
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47